Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A major obstacle to curing chronic myeloid leukemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)–persistent leukemic stem cells (LSC). These are BCR–ABL1 kinase independent, refractory to apoptosis, and serve as a reservoir to drive relapse or TKI resistance. We demonstrate that Polycomb Repressive Complex 2 is misregulated in chronic phase CML LSCs. This is associated with extensive reprogramming of H3K27me3 targets in LSCs, thus sensitizing them to apoptosis upon treatment with an EZH2-specific inhibitor (EZH2i). EZH2i does not impair normal hematopoietic stem cell survival. Strikingly, treatment of primary CML cells with either EZH2i or TKI alone caused significant upregulation of H3K27me3 targets, and combined treatment further potentiated these effects and resulted in significant loss of LSCs compared to TKI alone, in vitro, and in long-term bone marrow murine xenografts. Our findings point to a promising epigenetic-based therapeutic strategy to more effectively target LSCs in patients with CML receiving TKIs. Significance: In CML, TKI-persistent LSCs remain an obstacle to cure, and approaches to eradicate them remain a significant unmet clinical need. We demonstrate that EZH2 and H3K27me3 reprogramming is important for LSC survival, but renders LSCs sensitive to the combined effects of EZH2i and TKI. This represents a novel approach to more effectively target LSCs in patients receiving TKI treatment. Cancer Discov; 6(11); 1248–57. ©2016 AACR. See related article by Xie et al., p. 1237. This article is highlighted in the In This Issue feature, p. 1197
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“The epigenetic “writer” complex PRC2 is fundamental for defining stem cell identity where it primarily regulates gene repression using H3K27me3 (8).”
BackgroundInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 1×
“However, little is known about the role of EZH2 in CML, and unlike other myeloid malignancies, inactivating mutations of EZH2 in CML are rare (11, 12), although upregulation of EZH2 can result in a form of myeloproliferative disease (13).”
BackgroundCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · cited 2×
“As TKI-persistent cells are refractory to apoptosis (6, 7), we examined the mechanism of action of combined DAS plus EZH2i on the mRNA expression of a set of genes, including 14 H3K27me3 targets from apoptotic pathways (Fig.”
BackgroundHidalgo, I., Herrera-Merchan, A., Ligos, J. M., Carramolino, L., Nuñez, J., Martinez, F., Dominguez, O., Torres, M., & Gonzalez, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.08.001 · Cited by 222 · cited 8×
“In agreement with previous observations (14), we found no evidence that H3K27me3 levels were linked to changes in gene expression during normal cell fate decisions (HSC → HPC; Fig.”
BackgroundResultInfluential
Cited by
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Self-citationThe chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Self-citationTherapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Huang, X., Yan, J., Zhang, M., Wang, Y., Chen, Y., Fu, X., Wei, R., Zheng, X.-L., Liu, Z., Zhang, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.058 · Cited by 264
Arechederra, M., Daian, F., Yim, A., Bazai, S. K., Richelme, S., Dono, R., Saurin, A. J., Habermann, B. H., & Maina, F. (2018) · Nature Communications · doi:10.1038/s41467-018-05550-5 · Cited by 221
Patel, A. B., O’Hare, T., & Deininger, M. W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.007 · Cited by 204
“Two recent publications have highlighted the importance of EZH2 misregulation and its association with reprogramming of H3K27me3 targets in LSCs, resulting in LSC protection from apoptosis and TKI resistance.(68,69) EZH2 inactivation was shown to delay the development of leukemia and prolong survival in mouse models o…”
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Loscocco, F., Visani, G., Galimberti, S., Curti, A., & Isidori, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00939 · Cited by 120
Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0684-5 · Cited by 67
Self-citationPolycomb repressive complexes in hematological malignancies
Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55
Metadata
- Authors
- Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E. M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M., Dunn, K., Jorgensen, H. G., Cassels, J. E., Hamilton, A., Crossan, A., Sinclair, A., Holyoake, T. L., & Vetrie, D.
- Venue
- Cancer Discovery
- Published
- 2016-11-01
- Volume
- 6
- Issue
- 11
- Pages
- 1248-1257
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2520339276
- Cited by
- 144
- References
- 5
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.